Molecule Details
| InChIKey | KSMZEXLVHXZPEF-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.32 |
| Source | ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB11885 |
|---|---|
| Drug Name | Anlotinib |
| CAS Number | 1058156-90-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer. |
Categories: Heterocyclic Compounds, Fused-Ring
Cross-references: CHEMBL4303201 ChemSpider: 45743493 PubChem:25017411 PubChem:347828221 ZINC: ZINC000117924202
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P12931 | SRC | Proto-oncogene tyrosine-protein kinase Src | inhibitor | targets |